Withdrawn application: Lutholaz, Date of withdrawal: 19/07/2023, Initial authorisation

Human medicines European public assessment report (EPAR): Rebetol, ribavirin, Hepatitis C, Chronic, Date of authorisation: 06/05/1999, Revision: 39, Status: Withdrawn

Praziquantel (fin fish): European public MRL assessment report (EPMAR) - CVMP

Human medicines European public assessment report (EPAR): Zejula, niraparib, Fallopian Tube Neoplasms;Peritoneal Neoplasms;Ovarian Neoplasms, Date of authorisation: 16/11/2017, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Leukemia, Myeloid, Acute, Date of authorisation: 24/10/2019, Revision: 5, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): daprodustat, decision type: , therapeutic area: , PIP number: P/0242/2022

Opinion/decision on a Paediatric investigation plan (PIP): Calcipotriol, decision type: , therapeutic area: , PIP number: P/0153/2015

Clinical Trials Information System (CTIS) bitesize talk: Training materials, CTIS pre-requisites, and updates on transparency rules, Online, 15:30, from 29/11/2023 to 29/11/2023

Quick guide: Clinical Study Reports submission - CTIS Training Programme - Module 13

Human medicines European public assessment report (EPAR): Lacosamide UCB, lacosamide, Epilepsies, Partial, Date of authorisation: 26/08/2019, Revision: 6, Status: Authorised